Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Arena Reapplying for Approval of Lorcaserin

By Drug Discovery Trends Editor | December 22, 2010

SAN DIEGO (AP) – Arena Pharmaceuticals Inc. said it plans to again ask the Food and Drug Administration to approve its experimental weight-loss drug lorcaserin by the end of 2011, following the agency’s recent rejection over safety concerns.

Lorcaserin, being developed with Eisai Inc., is Arena’s most advanced clinical product and a major potential revenue producer. The company made the announcement after it completed a review meeting with the agency. It said it will continue to “refine elements” of its plan to again ask for approval.

In October, the agency rejected lorcaserin and potential competitor Vivus Inc.’s Qnexa because of safety concerns. Both the drugs had been given negative recommendations by an FDA panel of experts prior to the agency’s rejection. Specifically, the agency was concerned that about tumors seen in rats in early-stage lorcaserin testing, one of the factors that Arena Pharmaceuticals said the FDA had cited in a letter responding to the company’s application. In addition, the FDA has said the drug was only marginally effective in overweight and obese individuals without type 2 diabetes.

Meanwhile, competitor Vivus plans on meeting with the agency in January and has already asked European regulators to approve Qnexa. The FDA rejected the drug initially because of concerns over potential heart problems and birth defects.

So far, Orexigen Therapeutics Inc.’s Contrave is the only weight-loss drug to gain a positive recommendation from a panel of FDA experts. The FDA is scheduled to make a decision on the drug by Jan. 31.

Date: December 22, 2010
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE